CMPSN Stock Chart & Stats
$241.00
-$31.00(-12.81%)
At close: 4:00 PM EDT
$241.00
-$31.00(-12.81%)
Day’s Range― - ―
52-Week Range$91.00 - $260.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$30.10B
Enterprise Value$1.53B
Total Cash (Recent Filing)$433.30M
Total Debt (Recent Filing)$54.63M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 03, 2026EPS Estimate
-6.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.57
Shares Outstanding138,476,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$470.34Price Target Upside95.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-42.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase III Clinical EfficacyStrong Phase III results with rapid and durable effects materially improve COMP360’s probability of regulatory approval and commercial adoption. Demonstrated six-month durability also supports a differentiated therapeutic profile and may strengthen the company’s positioning in treatment-resistant depression.
Cash Runway And Low LeverageA substantial cash balance and minimal debt provide financial flexibility while the company completes regulatory review and prepares for launch. This runway reduces near-term financing pressure and allows continued investment in clinical, regulatory, and commercial infrastructure before revenue begins.
Commercial Launch ReadinessExisting treatment-site infrastructure, high stated prescriber interest, and strategic collaborations create a foundation for broad initial deployment if approval is secured. These assets can shorten commercialization ramp time and support patient access without requiring an entirely new delivery network.
Bears Say
Pre-revenue Business ModelThe company has not yet demonstrated commercial revenue and continues to incur substantial losses while funding development activities. Until COMP360 is approved and launched, financial performance remains dependent on clinical progress and external capital rather than recurring operating income.
Persistent Cash BurnSustained negative cash flow consumes the resources needed to advance trials, complete regulatory work, and build commercial operations. Even with reported runway, continued burn could require future financing or constrain investment if approval, reimbursement, or launch timing takes longer than expected.
Regulatory And Reimbursement UncertaintyUncertain scheduling, approval-dependent REMS requirements, and unfinished payer negotiations could delay access after a potential approval. These factors may increase launch complexity, slow early prescription conversion, and postpone the point at which clinical progress translates into dependable commercial revenue.
COMPASS Pathways News
CMPSN FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $91.00 and its highest was $260.00 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $30.10B.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Nov 03, 2026 which is in 2 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Aug 05, 2026. The company reported -$35.319 earnings per share for the quarter, missing the consensus estimate of -$7.289 by -$28.03.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -6.82.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 138,476,820 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$35.319 in its last earnings report, missing expectations of -$7.289. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in MX:CMPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$470.34 (95.16% Upside)
$470.34 (95.16% Upside)
Blogger Sentiment
Bullish
MX:CMPSN Sentiment 96%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.65%
12-Months-Change
Fundamentals
Return on Equity
-398.21%
Trailing 12-Months
Asset Growth
71.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
COMPASS Pathways
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPSN Company Deck
CMPSN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and commercial momentum: highly statistically significant Phase III efficacy, demonstrated 6-month durability, a generally favorable safety profile, an active rolling NDA with modules under review, a healthy cash position ($433M) through 2028, extensive commercial hiring, strong prescriber interest (~90% willing to prescribe), and substantial launch planning (training, payer engagement, partnerships). Key risks highlighted are timing and sequencing uncertainties around DEA rescheduling and REMS finalization, ongoing payer negotiations, remaining 52-week safety data submission, and potential competitive entrants. On balance, the positive clinical results and robust launch preparedness materially outweigh the timing and regulatory uncertainties.View all MX:CMPSN earnings summariesCMPSN Stock 12 Month Forecast
Average Price Target
$470.34
▲(95.16% Upside)